SYMNET: A Study of Patient-Reported Outcomes (PROs) Associated with Lanreotide Autogel (LAN) for the Control of Carcinoid Syndrome (CS) Symptoms in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients (Pts)

#951

Introduction: Somatostatin analogs can reduce incidence/severity of CS symptoms but their impact on pt satisfaction needs further investigation.

Aim(s): To assess PROs during LAN treatment of CS in NET pts.

Materials and methods: At routine visit, CS-related diarrhea pts treated with LAN for >3 mos completed PRO questionnaires on satisfaction and symptoms associated with CS control. Investigators assessed pt characteristics as predictors for satisfaction.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Ruszniewski P, Caplin M, Valle J, Lombard-Bohas C, Poston G,

Keywords: PRO,